Inhibitory receptors on eosinophils: a direct hit to a possible Achilles heel?

Since their discovery, much data have been accumulated on eosinophil differentiation, morphology, trafficking, and anatomical location(s) in health and disease. Although "classic" activation pathways (such as cytokines, chemokines, proinflammatory components, and adhesion molecules) regulating eosinophil activation have been widely explored, the presence of other activation molecules that might be disease specific is limited. Furthermore, the expression and function of inhibitory receptors on eosinophils have received scant attention. The need to identify new pathways that regulate eosinophil activation is a crucial goal as it can expand our knowledge on this peculiar cell and provide insights into important queries regarding the physiologic function of eosinophils. Over the past several years, it has become increasingly apparent that eosinophils express several receptors belonging to the immunoglobulin superfamily. In this review, we summarize the current knowledge on the expression and function of new pathways that govern eosinophil activation. In addition, we will propose some hypotheses regarding the ability to use these pathways as a future therapeutic approach. In conclusion, we assume that targeting inhibitory receptors on eosinophils may provide opportunities for immunoregulatory therapy in the near future.

[1]  L. Moretta,et al.  Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  I. Bachelet,et al.  The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. , 2006, Blood.

[3]  M. Daëron,et al.  A Bispecific Antibody against Human Ige and Human Fcγrii That Inhibits Antigen-induced Histamine Release by Human Mast Cells and Basophils Hal-pasteur Author Manuscript , 2004 .

[4]  O. Mandelboim,et al.  2B4 (CD244) Is Expressed and Functional on Human Eosinophils1 , 2005, The Journal of Immunology.

[5]  David A. Williams,et al.  CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism. , 2005, Blood.

[6]  Megan E. McNerney,et al.  A new self: MHC-class-I-independent Natural-killer-cell self-tolerance , 2005, Nature Reviews Immunology.

[7]  B. Bochner,et al.  Mechanism of Siglec-8-induced human eosinophil apoptosis: role of caspases and mitochondrial injury. , 2005, Biochemical and biophysical research communications.

[8]  J. L. Kavanaugh,et al.  Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-γ (Mig, CXCL9) , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Trowsdale,et al.  You say ITAM and I say ITIM, let's call the whole thing off: the ambiguity of immunoreceptor signalling , 2006, European journal of immunology.

[10]  P. Moore,et al.  Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor. , 2001 .

[11]  Tominari Kobayashi,et al.  T-cell activation and cytokine production via a bispecific single-chain antibody fragment targeted to blood-stage malaria parasites. , 2003, Blood.

[12]  Min Zhang,et al.  A novel human immunoglobulin Fcγ–Fcɛ bifunctional fusion protein inhibits FcɛRI-mediated degranulation , 2002, Nature Medicine.

[13]  H. Broxmeyer,et al.  Abnormal Chemokine-Induced Responses of Immature and Mature Hematopoietic Cells from Motheaten Mice Implicate the Protein Tyrosine Phosphatase Shp-1 in Chemokine Responses , 1999, The Journal of experimental medicine.

[14]  G. Groenewegen,et al.  Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer , 1997, Cancer Immunology, Immunotherapy.

[15]  J. Phillips,et al.  Identification of tyrosine residues crucial for CD200R‐mediated inhibition of mast cell activation , 2006, Journal of leukocyte biology.

[16]  Nicolai V Bovin,et al.  Glycan Array Screening Reveals a Candidate Ligand for Siglec-8* , 2005, Journal of Biological Chemistry.

[17]  Hong Zhang,et al.  The Src family kinases Hck and Fgr negatively regulate neutrophil and dendritic cell chemokine signaling via PIR-B. , 2005, Immunity.

[18]  H. Rosenberg,et al.  Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens , 2001, Journal of leukocyte biology.

[19]  L. Álvarez-Vallina,et al.  Antibodies and gene therapy: teaching old 'magic bullets' new tricks. , 2004, Trends in immunology.

[20]  H. Katz.  Inhibitory receptors and allergy. , 2002, Current opinion in immunology.

[21]  D. Cosman,et al.  Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Ono,et al.  Modulation of Immune Complex–induced Inflammation In Vivo by the Coordinate Expression of Activation and Inhibitory Fc Receptors , 1999, The Journal of experimental medicine.

[23]  L. Weiner,et al.  Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. , 1995, Journal of hematotherapy.

[24]  I. Bachelet,et al.  Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. , 2006, The Journal of allergy and clinical immunology.

[25]  Kenneth G. C. Smith,et al.  Cutting Edge: TREM-Like Transcript-1, a Platelet Immunoreceptor Tyrosine-Based Inhibition Motif Encoding Costimulatory Immunoreceptor that Enhances, Rather than Inhibits, Calcium Signaling via SHP-2 1 , 2004, The Journal of Immunology.

[26]  A. Saxon,et al.  A chimeric human-cat fusion protein blocks cat-induced allergy , 2005, Nature Medicine.

[27]  L. Lanier,et al.  Immune inhibitory receptors. , 2000, Science.

[28]  I. Moura,et al.  Identification of FcαRI as an Inhibitory Receptor that Controls Inflammation: Dual Role of FcRγ ITAM , 2005 .

[29]  L. Moretta,et al.  p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells , 2001, Immunological reviews.

[30]  L. Weiner,et al.  Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FcγRIII , 1995 .

[31]  Eric O Long,et al.  Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). , 2005, Blood.

[32]  K. Spiekermann,et al.  Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. , 1996, Blood.

[33]  Wendy S. Becker,et al.  Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer , 2003, British Journal of Cancer.

[34]  B. Bochner,et al.  Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. , 2003, Blood.

[35]  N. James,et al.  A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer , 2001, British Journal of Cancer.

[36]  M. Neuberger,et al.  Deficiency in CD22, a B Cell–specific Inhibitory Receptor, Is Sufficient to Predispose to Development of High Affinity Autoantibodies , 1999, The Journal of experimental medicine.